Apellis Pharmaceuticals Bundle
Who owns Apellis Pharmaceuticals now?
Apellis transformed from a 2009 startup to a public biotech after its 2017 Nasdaq IPO; by 2024–2025 its largest holders are institutional investors, while founders and insiders retain minority stakes. The company commercializes complement-targeting drugs including SYFOVRE and EMPAVELI.
Institutional investors dominate Apellis ownership, with mutual funds, ETFs, and asset managers holding the largest blocks; insiders and founders hold a small percentage, and ownership shifts track clinical and commercial milestones. See Apellis Pharmaceuticals Porter's Five Forces Analysis.
Who Founded Apellis Pharmaceuticals?
Founders and early ownership at Apellis Pharmaceuticals centered on Cedric Francois, MD, PhD and Pascal Deschatelets, PhD, with seed investors and co-founding executives holding concentrated equity; detailed founder splits and vesting terms were not publicly disclosed but followed typical venture-backed biotech norms.
Founding team
Cedric Francois and Pascal Deschatelets co-founded Apellis and led scientific strategy around complement therapeutics.
Early equity
Initial equity was concentrated among founders, seed investors and angel backers focused on immunology and ophthalmology.
Vesting norms
Founder grants typically vested over four years with customary acceleration on change-of-control.
Governance
Board oversight and IP assignment clauses were adopted to align control with the development plan and investor protections.
Early funding
Seed and Series A capital funded pegcetacoplan development; preferred rounds later diluted founders to finance trials.
No public disputes
There are no public records of founder disputes; governance emphasized scientific leadership and investor oversight.
For context on later ownership evolution and institutional investors, see the detailed analysis in Growth Strategy of Apellis Pharmaceuticals.
Key points — Founders & early ownership
Primary facts on founders, early capitalization and governance norms relevant to Apellis ownership.
- Cedric Francois, MD, PhD and Pascal Deschatelets, PhD co-founded the company (2009–2011).
- Initial equity concentrated among founders and seed investors; exact splits not public.
- Founder vesting followed industry standard: 4-year schedules with change-of-control acceleration.
- Seed/Series A investors funded pegcetacoplan; later preferred rounds diluted founders to support clinical development.
Apellis Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Apellis Pharmaceuticals’s Ownership Changed Over Time?
Key events shaping Apellis Pharmaceuticals ownership include venture rounds (2012–2016) that concentrated institutional VC control, the Nov 2017 Nasdaq IPO (ticker APLS) that broadened ownership and raised about $150 million, and 2023–2024 FDA approvals and follow-on financings that shifted the cap table toward large institutional investors and healthcare specialists.
| Period | Ownership Dynamics | Notable Stakeholders / Effects |
|---|---|---|
| 2012–2016 | Venture financing rounds; founders diluted but kept board/executive influence | Institutional VCs held controlling stakes for clinical-stage governance |
| Nov 2017 IPO | Raised ~$150 million; market cap ~low-$1 billion | Shift to public investors: mutual funds, index funds, healthcare specialists |
| 2018–2022 | Follow-on offerings and ATMs funded trials and commercial build; insider ownership fell to single digits | Top institutional holders include BlackRock, Vanguard, Wellington, State Street |
| 2023–2024 | FDA approval of SYFOVRE and EMPAVELI expansion; additional commercial capital raises | Top 5 institutions often aggregate 30%–45%; top individual ~7%–12% |
SEC filings (10-K, DEF 14A, 13F) through 2024–2025 show no controlling shareholder; ownership is concentrated among large passive and active institutions while founders and executives retain minority common stock and option/RSU positions.
Ownership Snapshot and Governance
Institutional ownership rose as Apellis moved to commercial-stage, prompting stronger governance and investor scrutiny on safety, pricing, and market access.
- Top institutional holders frequently include BlackRock, Vanguard, State Street, Wellington
- Top 5 institutions commonly hold between 30%–45% of outstanding shares
- Insider ownership (officers/directors) generally in the single digits by 2024–2025
- Public filings remain the primary source to verify current Apellis investors and stake sizes
For further market and investor context, see Target Market of Apellis Pharmaceuticals
Apellis Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Apellis Pharmaceuticals’s Board?
Apellis Pharmaceuticals’ board is majority independent, led by CEO and scientific founder Cedric Francois as a management director; independent directors include industry veterans and investor representatives who oversee capital markets, R&D and commercialization strategies.
| Director | Role | Independence |
|---|---|---|
| Cedric Francois | Chief Executive Officer; Scientific founder | No |
| Independent Director A | Board Chair / Life-science veteran | Yes |
| Independent Director B | Investor representative (life-science fund) | Yes |
The board operates with standing committees—audit, compensation, nominating/governance and science—each chaired by independent directors, aligning governance with U.S. biotech norms and investor expectations.
Board composition and voting power
Apellis uses a single-class common stock (one-share-one-vote), so public institutional investors and specialist healthcare funds hold the largest voting influence while no dual-class or golden share exists.
- Board majority independent; CEO Cedric Francois is the sole management director.
- Committees (audit, compensation, nominating/governance, science) chaired by independents.
- Single-class voting: no supervoting founder shares; control dispersed among public shareholders.
- No recent proxy contests or activist campaigns that changed board control; say-on-pay and director elections follow ISS/Glass Lewis guidance.
For context on the company’s origins and governance evolution see Brief History of Apellis Pharmaceuticals; institutional ownership data (Vanguard, BlackRock, State Street stakes) and 2025 13F filings typically identify top holders and percentage positions in SEC filings and proxy statements.
Apellis Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Apellis Pharmaceuticals’s Ownership Landscape?
Since SYFOVRE's 2023 U.S. launch, Apellis Pharmaceuticals ownership shifted toward growth- and income-oriented institutions seeking ophthalmology cash flows, with index inclusion and large-fund buying through 2024–2025 amid post-marketing volatility and follow-on financings.
| Period | Ownership Trend | Key Impact |
|---|---|---|
| 2023 (post-launch) | Rotation to growth/income mutual funds and specialty healthcare investors; some hedge-driven turnover after safety updates | Higher trading volume; short-term volatility in market cap |
| 2024 | Net sales scaling; large funds increased positions per 13F; rising index ownership with benchmark inclusion | Expanded float and market-cap weight; improved liquidity |
| 2021–2024 capital markets | Follow-on offerings and ATMs funded launches and life‑cycle studies; modest dilution | Float and index weight rose; insider ownership remained low-single digits |
Capital structure changes were financing-driven rather than control-driven: no dual-class recapitalizations or leveraged buyouts occurred, and insider sales were largely 10b5-1 programmed tied to compensation vesting.
Institutional consolidation
By late 2024 and into 2025, Vanguard, BlackRock and State Street increased passive exposure across healthcare ETFs, contributing to a larger share of Apellis institutional ownership; combined passive ownership estimates were commonly reported in the low-to-mid teens percent range for comparable mid-cap biopharma stocks.
Activism and M&A backdrop
Sector-wide 2024–2025 trends show selective activist interest and consolidation via M&A; Apellis displayed institutional consolidation rather than founder control, with management signalling continued independence and focus on commercial execution.
Ownership transparency
Reliable sources for Apellis major shareholders and shifts remain SEC 13F filings, S-forms for dilution events and proxy statements; large-fund holdings increased in 2024 filings and retail ownership remained a minority portion of outstanding shares.
Where to read more
For context on competitors and market positioning see Competitors Landscape of Apellis Pharmaceuticals.
Apellis Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Apellis Pharmaceuticals Company?
- What is Competitive Landscape of Apellis Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of Apellis Pharmaceuticals Company?
- How Does Apellis Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of Apellis Pharmaceuticals Company?
- What are Mission Vision & Core Values of Apellis Pharmaceuticals Company?
- What is Customer Demographics and Target Market of Apellis Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.